BNBX · Bnb Plus Corp. · Financials
Market Cap
$867,611
Shares
6.20M
Volume · Jul 14
719.8K
Avg daily vol (3M)
1.04M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$2.14M
+1.1%
FY2025
Net Income
-$15.16M
-116.8%
FY2025
Gross Margin
39.26%
-6.9pp
FY2025
Operating Margin
-750.92%
-104.2pp
FY2025
Diluted EPS
-$134.23
+90.2%
FY2025
Operating Cash Flow
-$12.24M
+10.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.39M | $2.14M | $2.11M | $13.37M | $18.17M | $9.03M | $1.93M | $5.39M | $3.9M | $4.75M | $4.19M | $9.01M | $2.72M | $2.04M | $1.85M | $968.85K | $519.84K | |
| $34.57K | $192.92K | $176.3K | $75.33K | $7200 | $13.68K | -$115.83K | -$162.43K | -$9615 | $2763 | $11K | -$23.47K | -$11.03K | $1272 | -$643.06K | — | — | |
| $972.96K | $1.3M | $1.14M | $7.83M | $13.12M | $4.54M | $720.9K | $877.61K | $1.21M | $1.08M | $1.17M | $384.27K | — | — | — | — | — | |
| $1.42M | $838.91K | $974.84K | $5.53M | $5.05M | $4.48M | — | — | — | — | — | — | — | — | — | — | — | |
| — | 39.26% | 46.12% | 41.39% | 27.82% | 49.66% | — | — | — | — | — | — | — | — | — | — | — | |
| $4.42M | $6.02M | $3.59M | $3.74M | $3.93M | $4.16M | $3.32M | $2.97M | $2.75M | $2.28M | $3.7M | $2.58M | $1.3M | $692.48K | $432.67K | $268.88K | $75.96K | |
| $20.53M | $10.87M | $11.05M | $12.75M | $15.1M | $12.85M | $10.03M | $10.28M | $11.04M | $13.32M | $10.81M | $13.41M | $13.25M | $11.2M | $7.62M | $8.39M | $7.19M | |
| — | — | — | — | $0 | $68.98K | $129.44K | $129.43K | $177.87K | $483.82K | $254.28K | $96.89K | $92.8K | $163.4K | $272.84K | $363.79K | — | |
| $227.07K | $384.17K | $432.6K | $1.36M | $1.29M | $844.44K | $285.73K | $390.42K | $547.8K | $633.33K | $706.5K | $490.64K | $442.26K | $206.34K | $313.94K | $367.56K | $371.91K | |
| $36.12M | $16.89M | $14.64M | $16.49M | $19.02M | $17.83M | $13.64M | $13.64M | $14.34M | $16.49M | $15.22M | $16.48M | $14.99M | $12.21M | $8.36M | $9.03M | $7.64M | |
| -$34.7M | -$16.05M | -$13.67M | -$10.95M | -$13.97M | -$13.35M | -$12.53M | -$9.12M | -$11.65M | -$12.82M | -$12.2M | -$7.85M | -$12.27M | -$10.18M | -$6.51M | -$8.06M | -$7.12M | |
| — | -750.92% | -646.72% | -81.94% | -76.89% | -147.86% | -648.98% | -169.31% | -298.37% | -269.83% | -291.41% | -87.18% | -450.96% | -499.74% | -350.87% | -831.55% | -1369.07% | |
| -$34.47M | -$15.66M | -$13.24M | -$9.59M | -$12.68M | -$12.5M | -$12.25M | -$8.73M | -$11.1M | -$12.19M | -$11.49M | -$7.36M | -$11.83M | -$9.97M | -$6.19M | -$7.69M | -$6.75M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -$1272 | $643.06K | $2.46M | $792.55K | |
| $37.85K | $192.92K | $120.48K | $75.33K | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $91.45K | -$106.58K | -$8877 | $642 | -$47.31K | -$8756 | -$378.08K | -$43.3K | -$37.01K | -$38.39K | $12.88K | -$28.31K | $123.91K | -$3761 | — | — | — | |
| -$36.01M | -$15.64M | -$6.79M | -$10.02M | -$8.27M | -$14.28M | -$13.03M | -$8.62M | -$11.69M | -$12.86M | -$12.18M | -$11.88M | -$13.07M | -$17.69M | -$7.15M | -$10.52M | -$7.91M | |
| — | -$684.12K | $0 | $0 | $0 | $0 | $0 | $15K | $0 | $0 | $0 | — | — | — | — | — | — | |
| -$4.69M | -$15.16M | -$6.99M | -$9.95M | -$8.27M | -$14.29M | -$13.03M | -$8.62M | -$11.69M | -$12.86M | -$12.18M | -$11.88M | -$13.07M | -$17.69M | -$7.15M | -$10.52M | -$7.91M | |
| — | -709.46% | -330.85% | -74.41% | -45.51% | -158.25% | -674.46% | -160.01% | -299.56% | -270.58% | -290.84% | -131.89% | -480.18% | -868.59% | -385.55% | -1085.32% | -1521.53% | |
| -$94.35K | -$188.52K | -$95.79K | -$75.86K | -$2168 | $8003 | -$1685 | -$9323 | $0 | — | — | — | — | — | — | — | — | |
| -$35.31M | -$69.49M | -$7.23M | -$9.95M | -$8.38M | -$14.29M | -$13.03M | -$8.93M | -$11.69M | — | — | — | — | — | -$7.15M | -$10.52M | — | |
| USD/shares | $544.27 | -$134.23 | -$1,366.42 | -$11,407.50 | -$13,950.00 | -$31,050.00 | -$49,800.00 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | $544.27 | -$134.23 | -$1,366.42 | -$11,407.50 | -$13,950.00 | -$31,050.00 | -$49,800.00 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 517.67K | 5288 | 871.6947 | 597.8469 | 461.1333 | 261.2715 | 61.4539 | 49.1627 | 1758.5994 | 1579.5397 | 1262.5522 | 901.0345 | 782.0586 | 38.41K | 25.12K | — |
| shares | — | 517.67K | 5288 | 871.6947 | 597.8469 | 461.1333 | 261.2715 | 61.4539 | 49.1627 | 1758.5994 | 1579.5397 | 1262.5522 | 901.0345 | 55.97K | 46.16K | 25.12K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2025-12-31 | USD 48,861 | 10-Q filed 2026-02-12 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Asset Management median 3.65×
EV/EBIT
—
Asset Management median 16.83×
P/E (TTM)
—
Asset Management median 18.68×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| DNA Tagging and Security Products | $1,148,817 | $1,218,136 | — | — | — |
| Therapeutic DNA Production | $988,118 | $895,354 | — | — | — |
| DNA Tagging and Security Products | — | $1,218,136 | $1,148,766 | $1,574,301 | $1,730,568 |
| Mdx Testing Services | — | $1,317,930 | $11,152,392 | $16,155,021 | $6,737,851 |
| Therapeutic DNA Production | — | $895,354 | $1,066,285 | $439,355 | $559,319 |
| MDX Testing Services | — | $1,317,929 | — | — | — |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Asia and Other | $1,020,556 | $989,225 | — | — | — | — |
| Americas | $1,010,795 | $951,896 | $12,222,650 | $17,544,444 | $8,520,336 | — |
| Europe | $105,584 | $172,369 | $258,355 | $448,847 | $359,509 | $266,701 |
| Asia and Other | — | — | $886,438 | $175,386 | $147,893 | $499,476 |
| United States | — | — | — | — | — | $1,165,320 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Supply Chain | $1,148,816 | $1,208,696 | — | — | — | — |
| Large Scale Dna Production | $612,360 | $584,115 | — | — | — | — |
| Research and Development Services | $375,759 | $311,238 | — | — | — | — |
| Asset Marking | — | $9,441 | $311,809 | $534,594 | $458,409 | $404,888 |
| Clinical Laboratory Service Revenues | — | $1,317,930 | — | — | $4,794,154 | — |
| Clinical Laboratory Testing Services | — | — | — | — | $4,794,154 | $77,550 |
| Clinical Laboratory Testing Services Over Time | — | $1,285,320 | $3,540,456 | $5,127,953 | $562,500 | — |
| Clinical Laboratory Testing Services Point in Time | — | $32,610 | $7,612,975 | $10,398,782 | $4,231,654 | — |
| Diagnostic Kits | — | — | — | — | $1,972,209 | — |
| Large Scale DNA Production | — | $584,115 | $653,015 | — | — | $281,971 |
| Mdx Test Kits and Supplies | — | — | — | $628,286 | $1,972,209 | — |
| Research and Development Services | — | $311,238 | $421,585 | $592,001 | $799,718 | $1,128,511 |
| Supply Chain | — | $1,208,696 | $827,603 | $887,061 | $1,003,248 | $38,577 |
| Asset Marking | — | $9,441 | — | — | — | — |
| Clinical Laboratory Service Revenues | — | $1,330,849 | — | — | — | — |
| Product | — | $1,074,813 | — | — | $3,295,849 | — |
| Service | — | $1,038,677 | — | — | $937,735 | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| DNA Tagging and Security Products | -$911,139 | -$2,551,977 | — | — | — |
| Therapeutic DNA Production | -$9,302,642 | -$4,789,272 | — | — | — |
| DNA Tagging and Security Products | — | -$2,551,983 | -$3,550,794 | -$4,652,786 | -$4,823,348 |
| Mdx Testing Services | — | -$1,489,220 | $1,206,652 | -$464,894 | -$274,250 |
| Therapeutic DNA Production | — | -$4,789,268 | -$3,792,871 | -$4,497,699 | -$5,214,221 |
| MDX Testing Services | — | -$1,489,220 | — | — | — |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| DNA Tagging and Security Products | -79.3% | -209.5% | — | — | — |
| Therapeutic DNA Production | -941.5% | -534.9% | — | — | — |
| DNA Tagging and Security Products | — | -209.5% | -309.1% | -295.5% | -278.7% |
| Mdx Testing Services | — | -113% | 10.8% | -2.9% | -4.1% |
| Therapeutic DNA Production | — | -534.9% | -355.7% | -1023.7% | -932.2% |
| MDX Testing Services | — | -113% | — | — | — |